NORTHWEST BIOTHERAPEUTICS INC: income tax expense or benefit
Income tax expense or benefit for NORTHWEST BIOTHERAPEUTICS INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All NORTHWEST BIOTHERAPEUTICS INC financial histories
What this measure means
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
Exact concept: us-gaap:IncomeTaxExpenseBenefit. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2012-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -537,000 | USD | 2026-04-15 | 10-K · 0001104659-26-043806 |
| 2024-01-01 | 2024-12-31 | 0 | USD | 2026-04-15 | 10-K · 0001104659-26-043806 |
| 2023-01-01 | 2023-12-31 | 0 | USD | 2025-03-31 | 10-K · 0001410578-25-000598 |
| 2022-01-01 | 2022-12-31 | 0 | USD | 2024-03-05 | 10-K · 0001410578-24-000133 |
| 2021-01-01 | 2021-12-31 | 0 | USD | 2023-02-28 | 10-K · 0001410578-23-000185 |
| 2020-01-01 | 2020-12-31 | 0 | USD | 2022-03-01 | 10-K · 0001410578-22-000244 |
| 2019-01-01 | 2019-12-31 | 0 | USD | 2021-03-31 | 10-K · 0001104659-21-044832 |
| 2018-01-01 | 2018-12-31 | 0 | USD | 2020-03-16 | 10-K · 0001104659-20-034145 |
| 2017-01-01 | 2017-12-31 | 0 | USD | 2019-04-02 | 10-K · 0001144204-19-017803 |
| 2016-01-01 | 2016-12-31 | 0 | USD | 2018-04-17 | 10-K · 0001144204-18-020971 |
| 2015-01-01 | 2015-12-31 | 0 | USD | 2017-04-17 | 10-K · 0001144204-17-020754 |
| 2014-01-01 | 2014-12-31 | 0 | USD | 2016-03-16 | 10-K · 0001144204-16-088301 |
| 2013-01-01 | 2013-12-31 | 0 | USD | 2015-03-17 | 10-K · 0001144204-15-016579 |
| 2012-01-01 | 2012-12-31 | 0 | USD | 2014-04-01 | 10-K · 0001144204-14-020023 |
Related financial histories
- NORTHWEST BIOTHERAPEUTICS INC: total assets
- NORTHWEST BIOTHERAPEUTICS INC: total liabilities
- NORTHWEST BIOTHERAPEUTICS INC: stockholders equity
- NORTHWEST BIOTHERAPEUTICS INC: cash and cash equivalents
- NORTHWEST BIOTHERAPEUTICS INC: net income or loss
- NORTHWEST BIOTHERAPEUTICS INC: operating cash flow
- NORTHWEST BIOTHERAPEUTICS INC: capital expenditure payments
- NORTHWEST BIOTHERAPEUTICS INC: revenue
- NORTHWEST BIOTHERAPEUTICS INC: contract revenue excluding tax
- NORTHWEST BIOTHERAPEUTICS INC: financing cash flow
- NORTHWEST BIOTHERAPEUTICS INC: investing cash flow
- NORTHWEST BIOTHERAPEUTICS INC: retained earnings or deficit
- NORTHWEST BIOTHERAPEUTICS INC: basic weighted-average shares
- NORTHWEST BIOTHERAPEUTICS INC: diluted weighted-average shares
- NORTHWEST BIOTHERAPEUTICS INC: basic earnings per share
- NORTHWEST BIOTHERAPEUTICS INC: diluted earnings per share
- NORTHWEST BIOTHERAPEUTICS INC: net property, plant and equipment
- NORTHWEST BIOTHERAPEUTICS INC: share-based compensation expense
- NORTHWEST BIOTHERAPEUTICS INC: operating income or loss
- NORTHWEST BIOTHERAPEUTICS INC: current assets
- NORTHWEST BIOTHERAPEUTICS INC: interest expense
- NORTHWEST BIOTHERAPEUTICS INC: current liabilities
- NORTHWEST BIOTHERAPEUTICS INC: current accounts payable
- NORTHWEST BIOTHERAPEUTICS INC: goodwill carrying amount
- NORTHWEST BIOTHERAPEUTICS INC: common-stock repurchase payments
- NORTHWEST BIOTHERAPEUTICS INC: research and development expense
Inspect the source
- Entity
- NORTHWEST BIOTHERAPEUTICS INC / CIK 0001072379
- Captured
- 2026-09-20T05:19:52.407Z
- SEC response SHA-256
96ae5155e1f371497ff4e69acb04404a27b3c3c6ef981ce6f22dae4793393c44
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001072379.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))